115966-23-9
Product Name:
URODILATIN HUMAN
Formula:
C145H234N52O44S3
Synonyms:
Thr-Ala-Pro-Arg-Atrial Natriuretic Peptide
Inquiry
COMPUTED DESCRIPTORS
| Molecular Weight | 3505.9 g/mol |
|---|---|
| XLogP3 | -17.1 |
| Hydrogen Bond Donor Count | 60 |
| Hydrogen Bond Acceptor Count | 54 |
| Rotatable Bond Count | 88 |
| Exact Mass | 3504.6867173 g/mol |
| Monoisotopic Mass | 3503.6833625 g/mol |
| Topological Polar Surface Area | 1670 Ų |
| Heavy Atom Count | 244 |
| Formal Charge | 0 |
| Complexity | 8140 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 29 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently-Bonded Unit Count | 1 |
| Compound Is Canonicalized | Yes |
PRODUCT INTRODUCTION
description
Ularitide is a synthetic form of urodilatin, a naturally occurring human natriuretic peptide that is involved in regulating blood pressure and the excretion of water and sodium from the kidneys. Urodilatin is produced in the kidney and excreted into the urine, and thus exists in low levels naturally in the systemic blood circulation. When injected into the blood, ularitide appears to cause diuresis (urine output) and natriuresis (sodium excretion), as well as vasodilation. Ularitide is currently in Phase 2 development as a potential treatment for patients with acute decompensated heart failure (ADHF).